Various Life Sciences Markets Research Reports Elaborated by La Merie Publishing Now Available at MarketPublishers.com

LONDON – TD The Market Publishers, Ltd. is extremely happy to announce that topical La Merie Publishing research reports on various life sciences markets are now available in its online catalogue.

Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors. In 2015, three various PTH receptor agonists were approved for treatment of patients at high risk of having osteoporosis or hypoparathyroidism. In 2015, these products generated combined sales of USD 1.6 billion. The upcoming patent expiration of teriparatide, the comparatively easy production in Escherichia coli and blockbuster drug sales make teriparatide an alluring target for biosimilar product developments and also for next-gen enhanced PTH receptor agonists. The report assesses the present-day R&D for more advanced PTH-R agonists on the basis of drug delivery solutions or molecular variation and based on biosimilar products and developments in the markets. Furthermore, a listing of the different companies’ R&D pipelines of PTH receptor agonists is available, too …

Competitor Analysis: Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines. Until quite recently, the Zika virus was considered to be comparatively harmless with just 20% of infections leading to mild, short-lived symptoms like a headache, rash and conjunctivitis. Latest reports associating the current outbreak of South America’s Zika virus disease to an upsurge in the number of babies with microcephal born in Brazil and cases of Guillain-Barré syndrome in El Salvador have induced a re-evaluation. The severity of these diseases heightens drug industry’s interest in the development of vaccines. Efforts will likely put into modifying vaccines for pertinent diseases. The study offers a compilation of presently active projects vaccines targeting the 7 flaviruses in question …

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update. Therapeutic antibodies targeting VEGF receptor or vascular endothelial growth factor are an extremely successful product class, generating total sales of USD 15 billion as of 2015. Whilst Avastin has been deemed as a blockbuster biologic, anti-VEGF products Eylea and Lucentis for treatment of retinal disorders registered higher sales for the first time ever in 2015 versus the anti-VEGF/R products for treating cancer. The commercial effectiveness of Avastin as a single product approved for a slew of cancer indications and the oncoming patent expiries in the leading markets have attracted a range of biosimilar drug developments in advanced clinical stages. More information on the sector can be found in the report …

More reports by the publisher can be found at La Merie Publishing page. 

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com 
MarketPublishers.com